{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:15:11Z","timestamp":1773281711551,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s12325-014-0151-7","type":"journal-article","created":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T09:28:37Z","timestamp":1410427717000},"page":"932-944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products"],"prefix":"10.1007","volume":"31","author":[{"given":"G\u00e1bor","family":"Holl\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jouni","family":"Vuorinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juhani","family":"Tuominen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppo","family":"Huttunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auli","family":"Ropo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,12]]},"reference":[{"key":"151_CR1","first-page":"1134","volume":"42","author":"J Stjernschantz","year":"2001","unstructured":"Stjernschantz J. From PGF2\u03b1 -isopropyl ester to latanoprost: a review of the development of Xalatan. Investig Ophthalmol Vis Sci. 2001;42:1134\u201345.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"Suppl 1","key":"151_CR2","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0039-6257(02)00293-X","volume":"47","author":"MR Hellberg","year":"2002","unstructured":"Hellberg MR, McLaughlin MA, Sharif NA, et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv Ophthalmol. 2002;47(Suppl 1):S13\u201333.","journal-title":"Surv Ophthalmol"},{"issue":"Suppl 4","key":"151_CR3","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/S0039-6257(01)00224-7","volume":"45","author":"DF Woodward","year":"2001","unstructured":"Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45(Suppl 4):S337\u201345.","journal-title":"Surv Ophthalmol"},{"issue":"Suppl 1","key":"151_CR4","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0039-6257(02)00323-5","volume":"47","author":"KM Maxey","year":"2002","unstructured":"Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol. 2002;47(Suppl 1):S34\u201340.","journal-title":"Surv Ophthalmol"},{"key":"151_CR5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/108076803762718105","volume":"19","author":"SS Davies","year":"2003","unstructured":"Davies SS, Ju WK, Neufeld AH, Abran D, Chemtob S, Roberts LJ 2nd. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther. 2003;19:45\u201354.","journal-title":"J Ocul Pharmacol Ther"},{"key":"151_CR6","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.ophtha.2004.06.028","volume":"111","author":"CB Camras","year":"2004","unstructured":"Camras CB, Toris CB, Sj\u00f6quist B, et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology. 2004;111:2193\u20138.","journal-title":"Ophthalmology"},{"key":"151_CR7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/pr.110.003517","volume":"63","author":"DF Woodward","year":"2011","unstructured":"Woodward DF, Jones RL, Narumiya S. International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15\u00a0years of progress. Pharmacol Rev. 2011;63:471\u2013538.","journal-title":"Pharmacol Rev"},{"key":"151_CR8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.exer.2003.12.007","volume":"78","author":"Y Takagi","year":"2004","unstructured":"Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:767\u201376.","journal-title":"Exp Eye Res"},{"key":"151_CR9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/bjo.2006.105585","volume":"91","author":"T Ota","year":"2007","unstructured":"Ota T, Aihara M, Saeki T, Narumiya S, Araie M. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. Br J Ophthalmol. 2007;91:673\u20136.","journal-title":"Br J Ophthalmol"},{"key":"151_CR10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archopht.1977.04450040067008","volume":"95","author":"TJ Zimmerman","year":"1977","unstructured":"Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;95:601\u20134.","journal-title":"Arch Ophthalmol"},{"key":"151_CR11","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/archopht.1979.01020010312004","volume":"97","author":"TJ Zimmerman","year":"1979","unstructured":"Zimmerman TJ, Kass MA, Yablonski ME, Becker B. Timolol maleate: efficacy and safety. Arch Ophthalmol. 1979;97:656\u20138.","journal-title":"Arch Ophthalmol"},{"key":"151_CR12","unstructured":"Juzych MS, Zimmerman TJ. Beta blockers. In: Zimmerman TJ, Kooner KS, Sharil M, Fechtner RD, editors. Textbook of ocular pharmacology. Philadelphia: Lippincott-Raven Publishers; 1997. p. 261\u2013275."},{"key":"151_CR13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00417-002-0553-0","volume":"240","author":"N Pfeiffer","year":"2002","unstructured":"Pfeiffer N. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefe\u2019s Arch Clin Exp Ophthalmol. 2002;240:893\u20139.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"151_CR14","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/archopht.120.7.915","volume":"120","author":"EJ Higginbotham","year":"2002","unstructured":"Higginbotham EJ, Feldman R, Stiles M, Dubiner H, For the Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy. One-year randomized trial. Arch Ophthalmol. 2002;120:915\u201322.","journal-title":"Arch Ophthalmol"},{"key":"151_CR15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ajo.2005.02.058","volume":"140","author":"JS Schuman","year":"2005","unstructured":"Schuman JS, Kats GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%\/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005;140:242\u201350.","journal-title":"Am J Ophthalmol"},{"key":"151_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2005.02.043","volume":"140","author":"HS Barnebey","year":"2005","unstructured":"Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004\u00a0%\/timolol 0.5\u00a0% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140:1\u20137.","journal-title":"Am J Ophthalmol"},{"key":"151_CR17","doi-asserted-by":"crossref","unstructured":"Hommer A, Ganfort\u00ae Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatorpost 0.03\u00a0%\/timolol 0.5\u00a0% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:53\u201362.","DOI":"10.1177\/112067210701700108"},{"key":"151_CR18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/IJG.0b013e3181507313","volume":"17","author":"JD Brandt","year":"2008","unstructured":"Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I, For the Ganfort\u00ae Investigators Group II. Bimatoprost\/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008;17:211\u20136.","journal-title":"J Glaucoma"},{"key":"151_CR19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/IJG.0b013e3181bdb586","volume":"19","author":"RA Lewis","year":"2010","unstructured":"Lewis RA, Gross RL, Sall KN, Schiffman RM, Liu CC, Batoosingh AL, For the Ganfort\u00ae Investigators Group II. The safety and efficacy of bimatoprost\/timolol fixed combination: a 1-year double-masked, randomized, parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2010;19:424\u20136.","journal-title":"J Glaucoma"},{"key":"151_CR20","doi-asserted-by":"crossref","unstructured":"Pfeiffer N, Traverso CE, Lorenz K, et al., For the Preservative-free Tafluprost Fixed Combination Study Group. A six month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015\u00a0% and timolol 0.5\u00a0% versus each of its individual preservative-free components. Adv Ther 2014 (submitted).","DOI":"10.1007\/s12325-014-0163-3"},{"key":"151_CR21","first-page":"234","volume":"26","author":"SC Patel","year":"1995","unstructured":"Patel SC, Spaeth GL. Compliance in patients prescribed eye drops for glaucoma. Ophthalmic Surg. 1995;26:234\u20136.","journal-title":"Ophthalmic Surg"},{"key":"151_CR22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ophtha.2005.10.034","volume":"113","author":"B Sleath","year":"2006","unstructured":"Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431\u20136.","journal-title":"Ophthalmology"},{"key":"151_CR23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","volume":"144","author":"AL Robin","year":"2007","unstructured":"Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533\u201340.","journal-title":"Am J Ophthalmol"},{"key":"151_CR24","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1517\/14656566.2014.936850","volume":"15","author":"G Holl\u00f3","year":"2014","unstructured":"Holl\u00f3 G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014;15:1737\u201347.","journal-title":"Expert Opin Pharmacother"},{"key":"151_CR25","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.clinthera.2004.10.009","volume":"26","author":"K Olander","year":"2004","unstructured":"Olander K, Zimmerman TJ, Downes N, Schoenfelder J, For the Xalacom\u00ae\/Latanoprost Study Group. Switching from latanoprost to the fixed combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension. Clin Ther. 2004;26:1619\u201329.","journal-title":"Clin Ther"},{"key":"151_CR26","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clinthera.2006.03.001","volume":"28","author":"WA Franks","year":"2006","unstructured":"Franks WA, Renard JP, Cunliffe IA, Rojanapongpun P. A 6-week double-masked, parallel-group study of the efficacy and safety of travoprost 0.004\u00a0% compared with latanoprost 0.005\u00a0%\/timolol 0.5\u00a0% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ther. 2006;28:332\u20139.","journal-title":"Clin Ther"},{"key":"151_CR27","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1142\/S0192415X14500578","volume":"127","author":"L Zhihong","year":"2014","unstructured":"Zhihong L, Mingchang Z, Yizhen H, et al. Safety and efficacy of bimatoprost\/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension. Chin Med J. 2014;127:905\u201310.","journal-title":"Chin Med J"},{"key":"151_CR28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14740338.6.1.45","volume":"6","author":"G Holl\u00f3","year":"2007","unstructured":"Holl\u00f3 G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6:45\u201352.","journal-title":"Expert Opin Drug Saf"},{"key":"151_CR29","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/01.ijg.0000176935.08392.14","volume":"14","author":"BA Hughes","year":"2005","unstructured":"Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004\u00a0%\/timolol 0.5\u00a0% ophthalmic solution compared to travoprost 0.004\u00a0% ophthalmic solution and timolol 0.5\u00a0% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14:392\u20139.","journal-title":"J Glaucoma"},{"key":"151_CR30","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1089\/jop.2013.0229","volume":"30","author":"G Holl\u00f3","year":"2014","unstructured":"Holl\u00f3 G, Hommer A, Ant\u00f3n L\u00f3pez A, Ropo A. Efficacy, safety and tolerability of preservative-free fixed combination of tafluprost 0.0015\u00a0%\/timolol 0.5\u00a0% versus concomitant use of the ingredients. J Ocul Pharmacol Ther. 2014;30:468\u201375.","journal-title":"J Ocul Pharmacol Ther"},{"key":"151_CR31","doi-asserted-by":"crossref","unstructured":"Goldberg I, Gil Pina R, Lanzagorta-Aresti A, Schiffman RM, Liu C, Bejanian M. Bimatoprost 0.03\u00a0%\/timolol 0.5\u00a0% preservative-free ophthalmic solution versus bimatoprost 0.03\u00a0%\/timolol 0.5\u00a0% (Ganfort\u00ae) for glaucoma or ocular hypertension: a 12-week randomized controlled trial. Br J Ophthalmol. 2014;98:926\u2013931.","DOI":"10.1136\/bjophthalmol-2013-304064"},{"key":"151_CR32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archophthalmol.2009.384","volume":"128","author":"EJ Higginbotham","year":"2010","unstructured":"Higginbotham EJ, Olander KW, Kim EE, Grunden JW, Kwok KK, Tressler CS, United States Fixed-Combination Study Group. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol. 2010;128:165\u201372.","journal-title":"Arch Ophthalmol"},{"key":"151_CR33","unstructured":"Astin M. A study on the vascular effects of prostaglandin F2\u03b1 and latanoprost in the eye with special reference to surface hyperemia after topical administration. Compr Summ Uppsala Univ dissertations Faculty of Medicine 1998. p.179."},{"key":"151_CR34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/108076803322660422","volume":"19","author":"NA Sharif","year":"2003","unstructured":"Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19:501\u201315.","journal-title":"J Ocul Pharmacol Ther"},{"key":"151_CR35","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12325-014-0125-9","volume":"31","author":"AG Konstas","year":"2014","unstructured":"Konstas AG, Voudouragkaki IC, Boboridis KG, et al. 24-hour efficacy of travoprost\/timolol BAK-free versus latanoprost\/timolol fixed combinations in patients insufficiently controlled with latanoprost. Adv Ther. 2014;31:592\u2013603.","journal-title":"Adv Ther"},{"key":"151_CR36","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/eye.2010.100","volume":"24","author":"AG Konstas","year":"2010","unstructured":"Konstas AG, Mikropoulos DG, Embesliis TA, et al. 24-h Intraocular pressure control with evening-dosed travoprost\/timolol, compared with latanoprost\/timolol fixed combinations in exfoliative glaucoma. Eye (Lond). 2010;24:1606\u201313.","journal-title":"Eye (Lond)"},{"key":"151_CR37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1755-3768.2007.01145.x","volume":"87","author":"AG Konstas","year":"2009","unstructured":"Konstas AG, Tsironi S, Vakalis AN, et al. Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. Acta Ophthalmol. 2009;87:71\u20136.","journal-title":"Acta Ophthalmol"},{"key":"151_CR38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/bjo.2008.155317","volume":"94","author":"AG Konstas","year":"2010","unstructured":"Konstas AG, Holl\u00f3 G, Mikropoulos D, et al. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost\/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol. 2010;94:209\u201313.","journal-title":"Br J Ophthalmol"},{"key":"151_CR39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ophtha.2005.06.027","volume":"113","author":"M Diestelhorst","year":"2006","unstructured":"Diestelhorst M, Larsson L-I, for the European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113:70\u20136.","journal-title":"Ophthalmology"},{"key":"151_CR40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/112067210701700206","volume":"17","author":"F Topouzis","year":"2007","unstructured":"Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004\u00a0%\/timolol 0.5\u00a0% to once-daily latanoprost 0.005\u00a0%\/timolol 0.5\u00a0% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:183\u201390.","journal-title":"Eur J Ophthalmol"},{"key":"151_CR41","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/112067211002000411","volume":"20","author":"P Palmberg","year":"2010","unstructured":"Palmberg P, Kim EE, Kwok KK, Tressler CS, Canada and United States Fixed Combination Latanoprost\/Timolol Study Group. A 12-week, randomized, double-masked study of fixed combination latanoprost\/timolol versus latanoprost or timolol monotherapy. Eur J Ophthalmol. 2010;20:708\u201318.","journal-title":"Eur J Ophthalmol"},{"key":"151_CR42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/OPTH.S8011","volume":"3","author":"MA Teus","year":"2009","unstructured":"Teus MA, Miglior S, Laganovska G, et al. Efficacy and safety of travoprost\/timolol vs dorzolamide\/timolol in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2009;3:629\u201336.","journal-title":"Clin Ophthalmol"},{"key":"151_CR43","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/eye.2011.134","volume":"25","author":"Y Kitazawa","year":"2011","unstructured":"Kitazawa Y, Smith P, Sasaki N, Kotake S, Bae K, Iwamoto Y. Travoprost 0.004\u00a0%\/timolol 0.5\u00a0%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Eye (Lond). 2011;25:1161\u20139.","journal-title":"Eye (Lond)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-014-0151-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T22:07:25Z","timestamp":1565820445000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-014-0151-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["151"],"URL":"https:\/\/doi.org\/10.1007\/s12325-014-0151-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}